If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Prophylactic medication after ileocaecal resection in patients with Crohn's disease reduces long-term rates of severe endoscopic recurrence and endoscopic or radiologic recurrence, serving as a ...

On this week’s program, how prescription drugs can be used as a window into much larger questions about medicine, culture and ...

Chelsea Boyd, Research Fellow, Integrated Harm Reduction, R Street Institute In SUPPORT of Senate Bill 195, “Pharmacies; pharmacists are authorized to dispense preexposure prophylaxis and postexposure ...